Isentress is the brand name for the antiretroviral medication raltegravir, a key component of HIV therapy. It is available as a 400 mg tablet and is prescribed in Hong Kong under the guidance of the Department of Health. This article explains how raltegravir works, its approved uses, safety considerations, and practical information for patients taking Isentress.
These indications follow the approval status granted by the Hong Kong regulatory authority, which aligns with international standards such as those of the U.S. FDA and the EU EMA.
Current peer-reviewed evidence does not support routine off-label use of raltegravir for conditions other than HIV infection. Clinical trials investigating its role in preventing mother-to-child transmission and in post-exposure prophylaxis have been conducted, but these uses remain under study and should only be considered within a clinical trial or specialist-guided protocol.
Absolute contraindications
Relative contraindications / cautions
Special populations
Major interactions
Rifampin (a strong inducer of CYP3A4 and UGT1A1) reduces raltegravir exposure; avoid co-administration or adjust dosing under specialist guidance.
Moderate interactions
Anticonvulsants such as carbamazepine or phenytoin may modestly lower raltegravir levels.
Methadone may have reduced efficacy; monitor withdrawal symptoms.
Mechanism of interaction
Raltegravir is metabolized primarily by UGT1A1 glucuronidation; drugs that induce or inhibit this pathway can alter its plasma concentration.
This article provides educational information about Isentress (raltegravir) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes. Raltegravir is meant to be part of a combination antiretroviral regimen. Your prescriber will choose companion drugs that complement its activity and minimize interaction risk.
No. Raltegravir can be taken with or without food. Consistency-taking it at the same times each day-helps maintain steady drug levels.
The 400 mg tablet typically bears the imprint “R200” on one side and “400” on the other, helping pharmacists verify authenticity.
Raltegravir is not screened for in standard occupational drug testing panels, as it is not a substance of abuse.
Yes, but carry the medication in its original pharmacy label, a copy of your prescription, and a brief physician letter if you need to cross customs with a controlled-substance declaration.
As of the latest regulatory updates, only the brand-name product Isentress is listed in Hong Kong’s pharmacopeia. Generic formulations may become available after patent expiry.
A mild rash can be common, but if it spreads, becomes painful, or is accompanied by fever, seek medical attention promptly, as it may signal a serious hypersensitivity reaction.
Both inhibit HIV integrase, but dolutegravir has a longer half-life allowing once-daily dosing. Choice of agent depends on resistance patterns, tolerability, and clinician judgment.
It is best to keep tablets in a dry place away from heat and humidity. A bathroom cabinet may expose them to moisture; a bedroom drawer at room temperature is preferable.
Some herbs (e.g., St. John’s wort) can induce drug-metabolizing enzymes and lower raltegravir levels. Discuss any supplement use with your healthcare provider before adding it to your regimen.
